→ Despite the success of anti-VEGF therapy for retinal diseases like nAMD, clinical trials report better outcomes than those observed in real-world clinical practice [1]. Many patients discontinue therapy prematurely [2a, 2b]. The upcoming approval of deepeye® TPS* (Therapy Planning Support) holds potential to improve both the efficiency and possibly even the effectiveness of IVOM therapy.

deepeye Medical originated from the IVOM-Portal of the AugenZentrum at St. Franziskus-Hospital Münster [3]. This network of over 60 ophthalmology practices has been utilizing peer-review for IVOM therapy decisions since 2011. The results are remarkable: a threefold improvement in visual acuity and double the therapy adherence compared to other real-world cohorts [2a, 2b]. The high adherence rate maintains 50% of the visual acuity gains even after 5 years [4, Figure 1].

Inspired by this, the AI assistant deepeye® TPS was trained on thousands of case histories spanning up to 10 years from over 200 ophthalmic centers, comprising millions of data points. It was validated through studies conducted with and by Novartis, Bayer, and Roche.

The functionality is impressively simple: medical staff can send SD-OCT scans of nAMD patients to the AI with just 1-2 clicks. The AI assistant analyzes the automatically anonymized OCT and delivers a report featuring:

• Assessment of disease activity.
• Prediction of treatment needs (12 months).
• Biomarkers (IRF, SRF, PED).
• Trend diagrams if prior images are available.**
• Summary for case documentation.**

Improving Cost-Effectiveness with the AI Assistant

The new collaboration between the physician and AI assistant offers potential to enhance therapy outcomes, reduce no-show patients, and thereby improve the financial stability of clinics. Overall, deepeye® TPS* provides the following advantages:

• Expert Time Savings: Supports treatment planning and patient education.
• User-Friendly: Simple operation for medical staff.
• Compatibility: Processes OCT images from all common OCT devices.
• Cost-Effectiveness: High ROI for busy IVOM centers.

‍

deepeye® TPS at AAD

deepeye® TPS* will be presented at the AAD Congress in Düsseldorf (March 19-22, 2025). Visit the booths of deepeye Medical (Booth No. 512), Heidelberg Engineering (No. 221), ZEISS (No. 226), and Topcon Healthcare (No. 245b), as well as one of the IVOM or AI seminars to learn more.

For further information about deepeye® TPS, visit www.deepeye-medical.com.

‍

Literature

1. R. Singh: “Real-world Experience with New Anti-VEGFs”. Retina Today, March 2022 Supplements. EURETINA education plattform. 

2a. N. Eter et al.: “PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration”. Graefes Arch Clin Exp Ophthalmol 259 (8),  2021 Aug, pp. 2213-2223

2b. F.G. Holz et al.: “Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.”.  Br J Ophthalmol.99 (2). 2015 Feb,pp. 220-226

3. K. Rothaus et al: “Analyse des Versorgungsmodells „Portal“ – Untersuchung der Ergebnisqualität der IVOM-Therapie im Hinblick auf Latenzzeiten bei exsudativer AMD.” Klin Monbl Augenheilkd. 2021 Mar;238(3):293-301.

4. L.Spickermann et al.: “Analyse des Versorgungsmodells „Portal“ – 4-Jahres Untersuchung der Ergebnisqualität der IVOM- Therapie in Hinblick auf Latenzzeiten bei exsudativer AMD”, DOG Congress 2024, Berlin. Presentation Fr20f-04

‍

*deepeye® TPS is intended for use by ophthalmologists to support treatment planning decisions for anti-VEGF therapy in patients with neovascular age-related macular degeneration (nAMD). CE marking is pending.

**future version

‍